Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot.

Teo JQ, Cai Y, Lim TP, Tan TT, Kwa AL.

Microorganisms. 2016 Feb 16;4(1). pii: E13. doi: 10.3390/microorganisms4010013. Review.

2.

New Delhi Metallo-β-Lactamase-Mediated Carbapenem Resistance: Origin, Diagnosis, Treatment and Public Health Concern.

Wei WJ, Yang HF, Ye Y, Li JB.

Chin Med J (Engl). 2015 Jul 20;128(14):1969-76. doi: 10.4103/0366-6999.160566. Review.

3.

Spectroscopic and mechanistic studies of heterodimetallic forms of metallo-β-lactamase NDM-1.

Yang H, Aitha M, Marts AR, Hetrick A, Bennett B, Crowder MW, Tierney DL.

J Am Chem Soc. 2014 May 21;136(20):7273-85. doi: 10.1021/ja410376s. Epub 2014 May 12.

4.

Molecular characterization of NDM-1 producing Enterobacteriaceae isolates in Singapore hospitals.

Teo J, Ngan G, Balm M, Jureen R, Krishnan P, Lin R.

Western Pac Surveill Response J. 2012 Mar 29;3(1):19-24. doi: 10.5365/WPSAR.2011.2.4.010. Print 2012 Jan.

5.

Search of potential inhibitor against New Delhi metallo-beta-lactamase 1 from a series of antibacterial natural compounds.

Thakur PK, Kumar J, Ray D, Anjum F, Hassan MI.

J Nat Sci Biol Med. 2013 Jan;4(1):51-6. doi: 10.4103/0976-9668.107260.

6.

Clinical correlates of New Delhi metallo-beta lactamase isolates--a survey of published literature.

Bhaskar E.

Indian J Med Res. 2012 Dec;136(6):1054-9. Review. No abstract available.

7.

Emergence of NDM-1 metallo-β-lactamase in Pseudomonas aeruginosa clinical isolates from Serbia.

Jovcic B, Lepsanovic Z, Suljagic V, Rackov G, Begovic J, Topisirovic L, Kojic M.

Antimicrob Agents Chemother. 2011 Aug;55(8):3929-31. doi: 10.1128/AAC.00226-11. Epub 2011 Jun 6.

8.

New metallo-β-lactamase: is its name after New Delhi helpful or harmful?

Jain M, John TJ.

Indian J Med Res. 2011 Apr;133:446-7. No abstract available.

Supplemental Content

Support Center